<DOC>
	<DOCNO>NCT01917643</DOCNO>
	<brief_summary>This study intend evaluate treatment effectiveness budesonide/formoterol ( BFC ) tiotropium tromide patient new ICS/LABA combination LAMA therapy .</brief_summary>
	<brief_title>Comparative Effectiveness Symbicort vs. Spiriva Among COPD Patients</brief_title>
	<detailed_description>Using US claim data HealthCore Integrated Research Environment , COPD patient â‰¥40 year old initiating BFC tiotropium 3/1/2009-2/28/2012 consider risk future exacerbation identify follow 12 month .</detailed_description>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Continuous health plan enrollment 12 month index Rx At least one prescription fill BFC tiotropium bromide intake period , naive ICS/LABA combination LAMA therapies year prior first prescription claim . COPD diagnosis , age 40 year age time first prescription At risk population COPD exacerbation ICS/LABA combination LAMA therapy preindex period Patients prescription claim budesonide/formoterol tiotropium bromide day Patients diagnose cancer Patients longterm OCS medication use preindex period</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>COPD , Comparative Effectiveness , Symbicort</keyword>
</DOC>